Company Number: 14402511

Analysis Date: 2025-07-20 14:08 UTC

1. Risk Rating: LOW
   CHRISTA GDP PHARMA LTD demonstrates a solid financial position with positive net assets and net current assets. The company is compliant with filing deadlines and there is no indication of insolvency or regulatory issues. The ownership and management structure is clear, with no apparent conflicts.

2. Key Concerns:

• Modest scale and early stage: Incorporated in late 2022, the company is relatively new and small, which inherently carries higher operational risk.
• Stock valuation: The addition of £7,216 in work in progress (stock) in the latest year requires monitoring to ensure realizable value and avoid obsolescence risk.
• Deferred tax liability: A new provision for deferred tax of £326 appears in 2025, which may affect future profitability or cash flow depending on timing and reversals.

3. Positive Indicators:

• Strong liquidity: Cash balances have increased to £24,091 with net current assets at £16,261, indicating good short-term liquidity and ability to meet obligations.
• Growing equity base: Shareholders’ funds nearly doubled from £9,401 in 2024 to £17,649 in 2025, reflecting retained profits and capital support.
• No overdue filings: Both accounts and confirmation statement are filed on time, demonstrating regulatory compliance and good governance.

4. Due Diligence Notes:

• Investigate the nature of the work in progress stock to assess conversion into revenue and risk of impairment.
• Review deferred tax notes to understand the source and timing of the deferred tax liability and its impact on cash flow.
• Confirm ongoing operational plans and client contracts given the company’s young age and limited employee base (average 1 employee).